Heart amyloid spotted by new PET tracer in pilot study

NCT ID NCT01683825

Completed Diagnosis Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether a radioactive tracer called F-18 florbetapir (Amyvid) can detect amyloid protein buildup in the heart using a PET scan. Researchers enrolled 23 people with known cardiac amyloidosis and a control group without the condition. The goal was to see if this non-invasive imaging method could accurately measure amyloid deposits, potentially offering a safer alternative to heart biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: F-18 florbetapir (Amyvid)
What this could lead to: If successful, this imaging method could provide a non-invasive way to diagnose and monitor cardiac amyloidosis, reducing the need for biopsies.
What could go wrong: This is a small pilot study with only 23 participants, so results may not apply broadly. The imaging technique may not be sensitive or specific enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Amyloid Neuropathies, Familial amyloidosis disease familial amyloid neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC AMYLOIDOSIS

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.